{"id":"NCT02252016","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)","officialTitle":"A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-22","primaryCompletion":"2015-12-07","completion":"2016-06-14","firstPosted":"2014-09-29","resultsPosted":"2017-01-19","lastUpdate":"2018-10-03"},"enrollment":159,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Grazoprevir + Elbasvir","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Immediate Treatment","type":"EXPERIMENTAL"},{"label":"Deferred Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multi-site, placebo-controlled trial of a fixed dose combination (FDC) of grazoprevir (MK-5172) 100 mg + elbasvir (MK-8742) 50 mg in participants with chronic Hepatitis C Virus (HCV) genotype (GT) 1, GT4 or GT6 with inherited blood disorders. The primary hypothesis is that the proportion of participants treated with grazoprevir+elbasvir achieving Sustained Virologic Response (SVR) 12 weeks after the end of all study therapy (SVR12) will be greater than the reference rate of 40%.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)","timeFrame":"12 weeks after completing study therapy (Week 24)","effectByArm":[{"arm":"Immediate Treatment","deltaMin":93.5,"sd":null},{"arm":"Deferred Treatment","deltaMin":91.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28256747","29461687"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":107},"commonTop":["Headache","Fatigue","Nausea","Asthenia","Arthralgia"]}}